Journal of Antimicrobial Chemotherapy · 2015 · 64 citations · 14 references
MedicineNephrologyPharmacotherapyRenal PathophysiologyRenal PharmacokineticsRenal PharmacotherapyRenal DiseaseRenal PharmacologyRenal ToxicityAntibiotic-induced NephrotoxicityCohort Study InvestigationMultidrug-resistant Gram-negative BacteriaNephrotoxic MedicationsPolymyxin ToxicityPrevalence RatePrevalence Rate AnalysisRenal Function Evaluation
OBJECTIVES: Polymyxin B is an active agent against many MDR Gram-negative bacteria, but nephrotoxicity is a major hindrance to its widespread use. To guide its optimal use, we determined the risk factors for nephrotoxicity onset associated with polymyxin B. METHODS: In a multicentre, retrospective, cohort study, we evaluated adult patients with normal renal function who received ≥72 h of polymyxin B therapy. Pertinent information was retrieved from medical records; patients were followed for up to 30 days after therapy was started. The primary endpoint of this study was the onset of nephrotoxicity. A Cox proportional hazards model was used for analysis. RESULTS: A total of 192 patients (52.1% male, 67.7% Caucasian) were evaluated. The mean ± SD age, actual body weight (ABW) and daily dose by ABW were 68.3 ± 17.2 years, 71.5 ± 20.4 kg and 1.5 ± 0.5 mg/kg, respectively. The median duration of therapy was 9.5 days. The overall prevalence rate of nephrotoxicity was 45.8% and the median onset of nephrotoxicity was 9 days. Independent risk factors for the onset of nephrotoxicity included daily dose by ABW (HR = 1.73; P = 0.022), concurrent use of vancomycin (HR = 1.89; P = 0.005) and contrast media (HR = 1.79; P = 0.009). Nephrotoxicity was seen earlier in the high-risk group (P = 0.003). CONCLUSIONS: Risk factors for nephrotoxicity onset associated with polymyxin B were identified. In conjunction with susceptibility and other pharmacokinetic/pharmacodynamic data, our results can be used to optimize treatment for MDR Gram-negative infections.
14
Gopi Patel, Shirish Huprikar, Stephanie H. Factor et al. · Infection Control and Hospital Epidemiology · 2008 · 838 citations
Life Sciences, Infectious Diseases, Antimicrobial Resistance +14
Pharmacodynamics of Polymyxin B against <i>Pseudomonas aeruginosa</i>
Vincent H. Tam, Amy N. Schilling, Giao Vo et al. · Antimicrobial Agents and Chemotherapy · 2005 · 206 citations
Darowan S. Akajagbor, Sharon Wilson, Kapana D. Shere-Wolfe et al. · Clinical Infectious Diseases · 2013 · 206 citations · Full text
John P. Ouderkirk, Jill A. Nord, Glenn Turett et al. · Antimicrobial Agents and Chemotherapy · 2003 · 189 citations · Full text
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +13
Kady Phe, Yuman Lee, Patrick M. McDaneld et al. · Antimicrobial Agents and Chemotherapy · 2014 · 181 citations · Full text
Medicine, Nephrology, Pharmacology +15